The Cost-Effectiveness of Immunotherapies for Advanced or Recurrent Endometrial Cancer: A Systematic Review

Previous PostIs Carer Burden a Given When Modelling Spinal Muscular Atrophy? Examining NICE Submissions
Next PostA Review and Evaluation of Reimbursement Outcomes for Non-orphan and Orphan drugs in Ireland in 2023